Payam Javan: It is expected by Thailand’s National Center for Genetic Engineering and Biotechnology for two COVID-19 anti-viral nasal sprays to enter human trials by the end of this year. The nasal sprays are based on adenovirus and influenza and testing on mice has provided promising results, Said deputy government spokeswoman Ratchada Thanadirek on Wednesday.
After pending approval is accepted by the country’s food and drug regulator, the first phase will begin later this year.
Developers claimed that their anti-viral nasal sprays may significantly reduce the infectivity of respiratory and cold viruses, including COVID-19 or any other diseases caused by the Chinese Communist Party (CCP) virus after doing a study on a similar pre-clinical product.
About 6.8 percent of Thailand’s population of more than 66 million people have received two doses of a vaccine as of August 11th.